BLFS: BioLife Solutions, Inc. Forward P/E Multiple

Graphic logo of BioLife (BLFS)

The BioLife Solutions, Inc. (BLFS) strategy is based on pricing power achieved through FDA protocols. The company's forward P/E metric, provided by the GURU.Markets platform, visualizes the path toward this goal, while the value of 134.00 captures the metric level. Growth is constrained by costs associated with smart containers and cloud monitoring, as well as a dependence on stable demand for cryopreservation consumables.

BLFS - biolifesolutions.com Price to Expected Earnings Ratio over the range 07/04/2022 - 10/18/2026

Financial and market metric breakdowns for BioLife (BLFS)

- stock value and consensus price forecast:
Basic company analysis:BLFS BioLife Solutions
Product sample of BioLife Solutions, Inc.

BioLife Solutions, Inc. (BLFS) revenues depend on the demand from biopharmaceutical centers for cryogenic equipment and specialized solutions. The company's forward P/E ratio correlates current market capitalization with expected annual earnings. Analyzing this metric allows for an assessment of the premium paid for future business growth. The trend in the company's forward P/E ratio reveals deviations of market value from fundamental expectations, helping investors determine the fairness of asset valuations.

Competitors of BioLife Solutions, Inc. (BLFS)

Future Price to Earnings Tempus Labs (TEM)|Future Price to Earnings QGEN (Qiagen NV)|Forward P/E Multiple IONS (Ionis Pharma)|Market Cap to Projected Earnings Repligen Inc. (RGEN)|Avidity Biosciences - Forward P/E Multiple|Price to Expected Earnings Ratio CRSP|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Pharmaceutical Inc. (RARE)|Projected Price to Earnings BEAM|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience (TWST)|Market Cap to Projected Earnings 10xgenomics.com|Future Price to Earnings Intellia Therapeutics, Inc. NTLA|Stoke Therapeutics Inc (STOK) - Projected Price to Earnings Ratio|WVE - Future Price to Earnings|MAZE: Future Price to Earnings|SION (Sionna Therapeutics Inc) - Projected Price to Earnings|primemedicine.com (PRME) - Forward P/E Multiple|Projected Price to Earnings TSHA|QURE (uniQure NV) - Market Cap to Future Earnings Ratio|Forward P/E Multiple MGTX|Market Cap to Projected Earnings REGENXBIO Corp|Future Price to Earnings Solid Biosciences Inc. SLDB|ocugen.com (OCGN) - Projected Price to Earnings Ratio|PACB - Future Price to Earnings|BNTC (Benitec Biopharma Inc) - Price to Future Earnings Ratio|Design Pharma (DSGN) - Future Price to Earnings|RCKT - Market Cap to Projected Earnings|Projected Price to Earnings FDMT|LXEO: Future Price to Earnings Multiple|Forward P/E Multiple KRRO|Market Cap to Projected Earnings Editas Medicine Inc|Future Price to Earnings Silence Therapeutics Inc. SLN|PRQR: Price to Future Earnings Ratio|Codexis Bio - Forward P/E Multiple|sangamo.com (SGMO) - Projected Price to Earnings|NAUT (nautilus.bio) - Projected Price to Earnings|MGX - Market Cap to Projected Earnings|DTIL (Precision BioSciences, Inc.) - Forward P/E Multiple|Future Price to Earnings GBIO|Future Price to Earnings Boundless Bio, Inc. (BOLD)|Future Price to Earnings XCUR (exicuretx.com)|Forward P/E Multiple IMNN (Imunon)|PHIO (Phio Pharmaceuticals Corp) - Price to Expected Earnings Ratio|MBIO - Future Price to Earnings|Market Cap to Projected Earnings TransCode Therapeutics RNAZ|BNGO: Forward P/E Multiple|Price to Future Earnings Ratio APDN|Future Price to Earnings bluebird bio|Price to Future Earnings Ratio IPA (ImmunoPrecise)|Forward P/E Multiple OMGA|Forward P/E Multiple Singular Genomics Corp (OMIC)|Forward P/E Multiple RGLS (Regulus Therapeutics)|syros.com - Future Price to Earnings|Telesis Bio - Forward P/E Multiple|Market Cap to Projected Earnings TRACON Pharmaceuticals Inc. TCON|Unity Bio (UBX) - Future Price to Earnings